PriceTargets.com logo

Novavax - NVAX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 330.38%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.95 As of 04/25/2024 01:00 AM ET
▼ -0.2 (-4.82%)

This chart shows the closing price for NVAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novavax Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVAX

Analyst Price Target is $17.00
▲ +330.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $17.00, with a high forecast of $19.00 and a low forecast of $15.00. The average price target represents a 330.38% upside from the last price of $3.95.

This chart shows the closing price for NVAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Novavax. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2024HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $19.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00N/A
8/9/2023B. RileyUpgradeNeutral ➝ Buy$15.00Low
5/10/2023HC WainwrightLower Target$110.00 ➝ $35.00N/A
4/20/2023TD CowenDowngradeOutperform ➝ Market PerformLow
3/1/2023B. RileyDowngradeBuy ➝ NeutralN/A
2/17/2023B. RileyLower Target$37.00 ➝ $29.00Low
2/13/2023HC WainwrightReiterated RatingBuy$110.00N/A
1/9/2023B. RileyLower TargetBuy$74.00 ➝ $37.00Low
12/30/2022HC WainwrightLower TargetBuy$207.00 ➝ $110.00Low
12/2/2022Jefferies Financial GroupInitiated CoverageHoldLow
11/10/2022B. RileyLower Target$83.00 ➝ $74.00Low
10/14/2022B. RileyLower TargetBuy$126.00 ➝ $83.00Low
10/13/2022CowenLower Target$55.00Low
9/22/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$132.00 ➝ $27.00Low
8/15/2022CowenLower Target$110.00N/A
8/9/2022CowenLower Target$150.00 ➝ $110.00N/A
8/9/2022CowenLower TargetOutperform$150.00 ➝ $110.00N/A
7/22/2022B. RileyLower Target$181.00 ➝ $171.00Low
6/8/2022Cantor FitzgeraldBoost Target$146.00 ➝ $168.00High
6/3/2022CowenReiterated RatingBuy$150.00High
5/20/2022Bank of AmericaInitiated CoverageUnderperform$35.00High
5/11/2022B. RileyLower Target$203.00 ➝ $181.00High
4/26/2022B. RileyLower TargetBuy$250.00 ➝ $203.00High
3/3/2022HC WainwrightLower TargetBuy$294.00 ➝ $207.00High
3/2/2022B. RileyLower Target$265.00 ➝ $250.00High
2/23/2022B. RileyLower TargetBuy$315.00 ➝ $265.00High
2/22/2022Jefferies Financial GroupInitiated CoverageBuy$198.00Medium
2/14/2022Cantor FitzgeraldLower TargetOverweight$282.00 ➝ $174.00High
1/21/2022CowenInitiated CoverageOutperform$150.00Medium
1/4/2022B. RileyBoost Target$305.00 ➝ $315.00Medium
12/21/2021JPMorgan Chase & Co.Boost TargetNeutral$172.00 ➝ $209.00High
9/1/2021Chardan CapitalReiterated RatingNeutralN/A
6/15/2021Cantor FitzgeraldBoost TargetReduce ➝ Overweight$217.00 ➝ $272.00High
5/18/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$285.00 ➝ $161.00Medium
5/12/2021B. RileyLower TargetBuy$365.00 ➝ $286.00High
5/12/2021Cantor FitzgeraldLower TargetOverweight$338.00 ➝ $217.00High
5/12/2021HC WainwrightLower TargetBuy$317.00 ➝ $294.00High
5/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$285.00 ➝ $161.00High
5/11/2021Jefferies Financial GroupLower TargetPositive ➝ Buy$310.00 ➝ $235.00Medium
3/12/2021HC WainwrightBoost TargetBuy$207.00 ➝ $317.00High
2/5/2021Cantor FitzgeraldBoost TargetOverweight$248.00 ➝ $338.00Low
2/1/2021B. RileyBoost TargetBuy$223.00 ➝ $334.00Low
1/29/2021Cantor FitzgeraldBoost TargetOverweight$211.00 ➝ $248.00High
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$200.00Low
11/17/2020HC WainwrightLower TargetBuy$290.00 ➝ $207.00Medium
10/22/2020B. RileyLower Target$223.00 ➝ $257.00Low
8/17/2020B. RileyReiterated RatingBuy$257.00High
8/5/2020LADENBURG THALM/SH SHDowngradeNeutral ➝ Sell$105.00High
8/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00 ➝ $275.00High
7/16/2020B. RileyBoost TargetBuy$106.00 ➝ $155.00Low
7/16/2020HC WainwrightBoost TargetBuy$101.00 ➝ $132.00High
7/8/2020LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral$50.00 ➝ $105.00High
7/7/2020Cantor FitzgeraldBoost Target$88.00 ➝ $148.00Medium
6/29/2020B. RileyBoost TargetBuy$74.00 ➝ $106.00High
6/29/2020HC WainwrightBoost TargetBuy$50.00 ➝ $101.00High
6/19/2020Cantor FitzgeraldBoost TargetOverweight$45.00 ➝ $88.00High
6/5/2020B. RileyBoost Target$61.00 ➝ $74.00Low
6/5/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$46.00High
6/3/2020B. RileyReiterated RatingBuy$61.00Low
5/26/2020B. RileyReiterated RatingBuy$53.00 ➝ $61.00High
5/18/2020B. RileyBoost TargetBuy$43.00 ➝ $53.00High
5/14/2020LADENBURG THALM/SH SHBoost Target$38.00 ➝ $50.00Low
5/12/2020Cantor FitzgeraldBoost TargetOverweight$23.00 ➝ $45.00High
5/12/2020OppenheimerBoost TargetOutperform$19.00 ➝ $38.50High
5/12/2020B. RileyBoost TargetBuy$29.00 ➝ $43.00High
5/12/2020HC WainwrightReiterated RatingBuy$33.00 ➝ $50.00High
4/30/2020HC WainwrightBoost TargetPositive ➝ Buy$24.00 ➝ $33.00Medium
4/24/2020B. RileyBoost TargetBuy$20.00 ➝ $29.00Low
4/9/2020LADENBURG THALM/SH SHReiterated RatingBuy$28.00Medium
4/8/2020B. RileyReiterated RatingBuy$20.00Low
3/27/2020B. RileyBoost Target$15.00 ➝ $20.00High
3/25/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$16.00 ➝ $23.00High
3/25/2020HC WainwrightBoost TargetBuy$17.00 ➝ $24.00High
3/24/2020B. RileyBoost TargetBuy$15.00 ➝ $20.00High
3/24/2020LADENBURG THALM/SH SHBoost TargetBuy$16.00 ➝ $24.00High
3/24/2020OppenheimerBoost Target$13.00 ➝ $19.00Medium
3/17/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$6.00 ➝ $16.00High
2/28/2020B. RileyBoost TargetBuy$12.00 ➝ $16.00High
2/27/2020HC WainwrightReiterated RatingBuyHigh
1/22/2020HC WainwrightInitiated CoverageBuy$17.00High
1/21/2020B. RileyReiterated RatingBuy$12.00High
11/27/2019B. RileyInitiated CoverageBuy$12.00High
11/8/2019LADENBURG THALM/SH SHReiterated RatingBuy$27.50Low
10/17/2019Cantor FitzgeraldReiterated RatingNeutralHigh
9/24/2019B. RileySet TargetBuy$35.00High
9/24/2019CitigroupLower TargetBuy$19.00 ➝ $15.00Low
9/10/2019OppenheimerLower TargetOutperform$25.00 ➝ $13.00Low
8/14/2019HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $17.00High
7/1/2019HC WainwrightReiterated RatingBuy ➝ Positive$10.00 ➝ $12.00High
6/13/2019HC WainwrightSet TargetBuy$10.00Medium
5/13/2019OppenheimerBoost Target$1.25 ➝ $25.00High
5/10/2019Chardan CapitalReiterated RatingNeutral$7.00N/A
5/9/2019Cantor FitzgeraldReiterated RatingHoldHigh
5/3/2019HC WainwrightReiterated RatingBuy$40.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 6 very positive mentions
  • 35 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 5 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 15 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 14 very positive mentions
  • 26 positive mentions
  • 12 negative mentions
  • 3 very negative mentions
Mentions as of
2/26/2024
  • 11 very positive mentions
  • 28 positive mentions
  • 15 negative mentions
  • 3 very negative mentions
Mentions as of
3/27/2024
  • 11 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 11 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Novavax logo
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $3.95
Low: $3.90
High: $4.12

50 Day Range

MA: $4.70
Low: $3.89
High: $6.02

52 Week Range

Now: $3.95
Low: $3.53
High: $11.36

Volume

3,365,238 shs

Average Volume

7,443,656 shs

Market Capitalization

$552.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Novavax?

The following Wall Street analysts have issued research reports on Novavax in the last twelve months: B. Riley, HC Wainwright, and StockNews.com.
View the latest analyst ratings for NVAX.

What is the current price target for Novavax?

2 Wall Street analysts have set twelve-month price targets for Novavax in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 330.4%. HC Wainwright has the highest price target set, predicting NVAX will reach $19.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $15.00 for Novavax in the next year.
View the latest price targets for NVAX.

What is the current consensus analyst rating for Novavax?

Novavax currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVAX will outperform the market and that investors should add to their positions of Novavax.
View the latest ratings for NVAX.

What other companies compete with Novavax?

Other companies that are similar to Novavax include BioCryst Pharmaceuticals, ProKidney, Prime Medicine, Allogene Therapeutics and Valneva. Learn More about companies similar to Novavax.

How do I contact Novavax's investor relations team?

Novavax's physical mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company's listed phone number is (240) 268-2000 and its investor relations email address is [email protected]. The official website for Novavax is www.novavax.com. Learn More about contacing Novavax investor relations.